在遗传视网膜疾病的基因疗法试验中临床试验终点的更新
Jane M Igoe1, Byron L Lam1, Ninel Z Gregori1,2
1Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Journal of clinical medicine
|September 28, 2024
概括
基因疗法为遗传性视网膜疾病 (IRD) 提供了希望,但新的结果措施至关重要. 需要专门的终点来准确评估这些多种视力丧失条件的治疗疗效.
科学领域:
- 眼科医生 眼科 眼科
- 遗传学 遗传学 是一个
- 医学研究 医学研究
背景情况:
- 遗传性视网膜疾病 (IRD) 是一种罕见的遗传疾病,导致逐渐视力丧失.
- 数以百计的遗传变异导致各种IRD表型和视力障碍.
- 当前的结果测量可能无法完全捕捉IRD中的治疗效果.
研究的目的:
- 审查目前对IRDs的基因治疗方法.
- 检查在IRD临床试验中测量视觉功能的各种终点.
- 突出最近基因疗法试验中使用的终点,并提供正在进行的试验概述.
主要方法:
- 对IRDs的基因疗法方法的文献综述.
- 在眼科试验中使用的结果指标的分析 (结构性,功能性,以患者为中心).
- 最近和正在进行的 (第2-3期) IRD基因疗法临床试验中的终点调查.
主要成果:
- 像视力敏度这样的标准结果措施可能不足以用于IRDs.
- 需要新的终点来评估外周视力,色彩视力和夜视力.
- 最近的试验越来越多地利用专门的终点来证明疗效.
结论:
- 在IRD中精确评估基因疗法的疗效需要量身定制的结果措施.
- 开发和验证独特的终点对于推进IRD治疗至关重要.
- 目前正在进行的临床试验正在探索解决IRD复杂性的创新策略.
相关概念视频
Gene Therapy
25.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.3K
iPS Cell Differentiation
2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K


